Cited by 341Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

Open access

Costa, João, Borges, Margarida, David, Cláudio, Carneiro, António Vaz·2006·BMJ

DOI 10.1136/bmj.38793.468449.aePMC PMC1459619

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane, Medline, Embase, and reference lists up to April 2004. STUDY SELECTION: Randomised, placebo controlled, double blind trials with a follow-up of at least three years that evaluated lipid lowering drug treatment in patients with and without diabetes mellitus. DATA EXTRACTION: Two independent reviewers extracted data. The primary outcome was major coronary events defined as coronary heart disease death, non-fatal myocardial infarction, or myocardial revascularisation procedures. RESULTS: Twelve studies were included. Lipid lowering drug treatment was found to be at least as effective in diabetic patients as in non-diabetic patients. In primary prevention, the risk reduction for major coronary events was 21% (95% confidence interval 11% to 30%; P < 0.0001) in diabetic patients and 23% (12% to 33%; P = 0.0003) in non-diabetic patients. In secondary prevention, the corresponding risk reductions were 21% (10% to 31%; P = 0.0005) and 23% (19% to 26%; P < or = 0.00001). However, the absolute risk difference was three times higher in secondary prevention. When results were adjusted for baseline risk, diabetic patients benefited more in both primary and secondary prevention. Blood lipids were reduced to a similar degree in both groups. CONCLUSIONS: The evidence that lipid lowering drug treatment (especially statins) significantly reduce cardiovascular risk in diabetic and non-diabetic patients is strong and suggests that diabetic patients benefit more, in both primary and secondary prevention. Future research should define the threshold for treatment of these patients and the desired target lipid concentrations, especially for primary prevention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.38793.468449.ae

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261

Show all 69 references

Research works printed but not linked: 1

Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.

Sorted by citations

Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ
Tong, A., Flemming, K., McInnes, E., Oliver, S., & Craig, J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-181 · Cited by 3,569
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J. P., Dralle, H., Ebeling, P. R., Melmed, S. K., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,500
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C., Hamilton, J. K., HAY, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,273
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies
Mazzone, T., Chait, A., & Plutzky, J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60768-0 · Cited by 552
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Bots, M. L., Visseren, F. L. J., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 458
Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study
Joshi, S., Anjana, R. M., Deepa, M., Pradeepa, R., Bhansali, A., Dhandhania, V. K., Joshi, P. P., Ranjit Unnikrishnan, I., Nirmal, E., Subashini, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096808 · Cited by 403
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
Strippoli, G. F., Navaneethan, S. D., Johnson, D. W., Perkovic, V., Pellegrini, F., Nicolucci, A., & Craig, J. C. (2008) · BMJ · doi:10.1136/bmj.39472.580984.ae · Cited by 399
Is diabetes a coronary risk equivalent? Systematic review and meta‐analysis
Bulugahapitiya, U., Siyambalapitiya, S., Sithole, J., & IDRIS, I. R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02640.x · Cited by 377
Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity
Bakker, W., Eringa, E. C., Sipkema, P., & van Hinsbergh, V. W. M. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0685-6 · Cited by 359
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
ReseArch with Patient and Public invOlvement: a RealisT evaluation – the RAPPORT study
Wilson, P., Mathie, E., Keenan, J., McNeilly, E., Goodman, C., Howe, A., Poland, F., Staniszewska, S., Kendall, S., Munday, D., et al. (2015) · Health Services and Delivery Research · doi:10.3310/hsdr03380 · Cited by 297
Diabetes and atherosclerosis: is there a role for hyperglycemia?
Chait, A., & Bornfeldt, K. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800059-jlr200 · Cited by 298
Helping Patients With Type 2 Diabetes Mellitus Make Treatment Decisions
Weymiller, A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.10.1076 · Cited by 278
Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Norris, S. L., Kansagara, D. L., Bougatsos, C., & Fu, R. F. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00008 · Cited by 226
American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219
Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials
Naci, H., Brugts, J. J., Fleurence, R., Tsoi, B., Toor, H., & Ades, A. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313480435 · Cited by 202
Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol
Bayturan, O., Kapadia, S., Nicholls, S. J., Tuzcu, E. M., Shao, M., Uno, K., Shreevatsa, A., Lavoie, A. J., Wolski, K., Schoenhagen, P., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.050 · Cited by 174
Essential Role of Insulin and Insulin-Like Growth Factor 1 Receptor Signaling in Cardiac Development and Function
Laustsen, P. G., Russell, S. J., Cui, L., Entingh-Pearsall, A., Holzenberger, M., Liao, R., & Kahn, C. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01110-06 · Cited by 173
Prevention and early detection of vascular complications of diabetes
Marshall, S. M., & Flyvbjerg, A. (2006) · BMJ · doi:10.1136/bmj.38922.650521.80 · Cited by 237
The Peroxisome Proliferator–Activated Receptor-γ Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance
Werner, C. M., Kamani, C. H., Gensch, C., Böhm, M., & Laufs, U. (2007) · Diabetes · doi:10.2337/db07-0069 · Cited by 159
Fibrates and future PPARα agonists in the treatment of cardiovascular disease
Staels, B., Maes, M., & Zambon, A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1278 · Cited by 169
HMG CoA reductase inhibitors (statins) for dialysis patients
Navaneethan, S. D., Nigwekar, S. U., Perkovic, V., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub3 · Cited by 158
How Patient Centered Are Medical Decisions?
Fowler, F. J., Gerstein, B. S., & Barry, M. J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6172 · Cited by 158
Creating a Conversation: Insights from the Development of a Decision Aid
Montori, V. M., Breslin, M., Maleska, M., & Weymiller, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040233 · Cited by 158
Serum Lipid Profile and Its Association with Diabetes and Prediabetes in a Rural Bangladeshi Population
Bhowmik, B., Siddiquee, T., Mujumder, A., Afsana, F., Ahmed, T., Mdala, I., Moreira, N. C. D. V., Khan, A. K. A., Hussain, A., Holmboe‐Ottesen, G., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15091944 · Cited by 169
Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation.
Gillett, M., Royle, P., Snaith, A., Scotland, G., Poobalan, A. S., Imamura, M., Black, C., Boroujerdi, M. A., Jick, S. S., Wyness, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16330 · Cited by 150
Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue With Lipoprotein Particle Number and Size in Type 2 Diabetes
Sam, S., Haffner, S. M., Davidson, M. H., D’Agostino, R. B., Feinstein, S. B., Kondos, G. T., Pérez, A., & Mazzone, T. (2008) · Diabetes · doi:10.2337/db08-0157 · Cited by 130
Relationship of cumulative exposure to the triglyceride-glucose index with ischemic stroke: a 9-year prospective study in the Kailuan cohort
Wang, X., Feng, B., Huang, Z., Cai, Z., Yu, X., Chen, Z., Cai, Z., Chen, G., Wu, S., & Chen, Y. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01510-y · Cited by 129
Ezetimibe/Simvastatin vs Atorvastatin in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia: The VYTAL Study
Goldberg, R. B., Guyton, J. R., Mazzone, T., Weinstock, R. S., Polis, A. B., Edwards, P., Tomassini, J. E., & Tershakovec, A. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.12.1579 · Cited by 121
Screening for Diabetes and Prediabetes
Duan, D., Kengne, A. P., & Echouffo-Tcheugui, J. B. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.002 · Cited by 131
Obesity and Insulin Resistance Promote Atherosclerosis through an IFNγ-Regulated Macrophage Protein Network
Reardon, C. A., Lingaraju, A., Schoenfelt, K. Q., Zhou, G., Cui, C., Jacobs-El, H., Babenko, I., Hoofnagle, A. N., Czyż, D. M., Shuman, H. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.010 · Cited by 102
The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
Toth, P. P., Simko, R. J., Palli, S. R., Koselleck, D., Quimbo, R. A., & Cziraky, M. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-109 · Cited by 93
Effects of the diabetes linked TCF7L2polymorphism in a representative older population
Melzer, D. R., Murray, A., Hurst, A. J., Weedon, M. N., Bandinelli, S., Corsi, A. M., Ferrucci, L., Paolisso, G., Guralnik, J. M., & Frayling, T. M. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-34 · Cited by 91
Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia
Haring, R., Baumeister, S. E., Völzke, H., Dörr, M., Felix, S. B., Kroemer, H. K., Nauck, M. A., & Wallaschofski, H. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32833c1a8d · Cited by 89
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease
Karmali, K. N., Lloyd‐Jones, D. M., Berendsen, M. A., Goff, D. C., Sanghavi, D. M., Brown, N. C., Korenovska, L., & Huffman, M. D. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0218 · Cited by 93
Diabetes guidelines: easier to preach than to practise?
Bryant, W., Greenfield, J. R., Chisholm, D. J., & Campbell, L. V. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00583.x · Cited by 88
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. D. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 89
Duration of obesity exposure between ages 10 and 40 years and its relationship with cardiometabolic disease risk factors: A cohort study
Norris, T., Cole, T. J., Bann, D., Hamer, M., Hardy, R., Li, L., Ong, K. K., Ploubidis, G. B., Viner, R., & Johnson, W. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003387 · Cited by 94
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study
Donnelly, L. A., Doney, A. S. F., Dannfald, J., Whitley, A. L., Lang, C. C., Morris, A. D., Donnan, P. T., & Palmer, C. N. A. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283106071 · Cited by 85
Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica
Ezquerra, E. A., Castellano, J. M., & Barrero, A. A. (2008) · Revista Española de Cardiología · doi:10.1157/13123996 · Cited by 95
Long‐term adherence to statin treatment in diabetes
Donnelly, L. A., Doney, A. S. F., Morris, A. D., Palmer, C. N. A., & Donnan, P. T. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02476.x · Cited by 84
Matrix Biology of Abdominal Aortic Aneurysms in Diabetes: Mechanisms Underlying the Negative Association
Norman, P. E., Davis, T. M. E., Le, M., & Golledge, J. (2007) · Connective Tissue Research · doi:10.1080/03008200701331524 · Cited by 82
An exploration of German and British physiotherapists' views on the effects of hippotherapy and their measurement
Debuse, D., Chandler, C., & Gibb, C. E. (2005) · Physiotherapy Theory and Practice · doi:10.1080/09593980500321143 · Cited by 83
Screening for Type 2 Diabetes and Dysglycemia
Echouffo-Tcheugui, J. B., Ali, M. K., Griffin, S. J., & Narayan, K. M. V. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxq020 · Cited by 87
An Overview of the Extra-Lipid Effects of Rosuvastatin
Kostapanos, M. S., Milionis, H. J., & Elisaf, M. (2008) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248408318628 · Cited by 78
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 78
Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes
Mazzone, T. (2010) · Circulation · doi:10.1161/circulationaha.109.913350 · Cited by 75
Diabetes Mellitus, ArterialWall, and Cardiovascular Risk Assessment
Kozàkovà, M., & Palombo, C. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13020201 · Cited by 74
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 80
Prevalence of dyslipidemia and its associated factors among Jordanian adults
Khader, Y. S., Batieha, A. M., El-Khateeb, M. S., Omari, M. A., & Ajlouni, K. M. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.12.004 · Cited by 73
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 76
A. qualitative exploration of the emotional wellbeing and support needs of new mothers from Afghanistan living in Melbourne, Australia
Russo, A., Lewis, B., Joyce, A., Crockett, B., & Luchters, S. (2015) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-015-0631-z · Cited by 68
Dyslipidemia
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications
Yan, M., Mehta, J. L., Zhang, W., & Hu, C. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6342-4 · Cited by 69
Triglycerides/HDL cholesterol ratio and type 2 diabetes incidence: Panasonic Cohort Study 10
Yuge, H., Okada, H., Hamaguchi, M., Kurogi, K., Murata, H., Ito, M., & Fukui, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02046-5 · Cited by 68
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Wilding, J. P. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01601.x · Cited by 71
Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)
Steinhagen‐Thiessen, E., Bramlage, P., Lösch, C., Hauner, H., Schunkert, H., Vogt, A., Wasem, J., Jöckel, K., & Moebus, S. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-31 · Cited by 68
The Therapeutic Role of Niacin in Dyslipidemia Management
Boden, W. E., Sidhu, M. S., & Toth, P. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413514481 · Cited by 69
Impact of an integrated care program on glycemic control and cardiovascular risk factors in patients with type 2 diabetes in Saudi Arabia: an interventional parallel-group controlled study
Tourkmani, A. M., Abdelhay, O., Alkhashan, H. I., Alaboud, A. F., Bakhit, A., Elsaid, T., Alawad, A., Alobaikan, A., Alqahtani, H., Alqahtani, A., et al. (2018) · BMC Family Practice · doi:10.1186/s12875-017-0677-2 · Cited by 70
The Interdependency and Co-Regulation of the Vitamin D and Cholesterol Metabolism
Warren, T., McAllister, R., Morgan, A. E., Singh, T., McGilligan, V., Ennis, M., Page, C. J., Kelly, C., Peace, A. J., Corfe, B. M., et al. (2021) · Cells · doi:10.3390/cells10082007 · Cited by 68
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality
Stafylas, P. C., Sarafidis, P. A., & Lasaridis, A. N. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.005 · Cited by 64
Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region
Kengne, A., Patel, A., Barzi, F., Jamrozik, K., Lam, T., Ueshima, H., Ohkubo, T., Kim, H., Xianghua, F., & Woodward, M. (2007) · Diabetologia · doi:10.1007/s00125-007-0801-2 · Cited by 55
Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies
Laxy, M., Knoll, G., Schunk, M. V., Meisinger, C., Huth, C., & Holle, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164704 · Cited by 64
Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy
Ezquerra, E. A., Castellano, J. M., & Barrero, A. A. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60212-1 · Cited by 65
The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock
Kengne, A. P., Turnbull, F., & MacMahon, S. W. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.02.010 · Cited by 65
Abdominal aortic aneurysms and diabetes mellitus
Pafili, K., Gouni‐Berthold, I., Παπάνας, Ν., & Mikhailidis, D. P. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.08.011 · Cited by 60
Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
Katsiki, N., Banach, M., & Mikhailidis, D. P. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.89449 · Cited by 61
Optimization of caseinate-coated simvastatin-zein nanoparticles: improved bioavailability and modified release characteristics
Ahmed, O. A. A., Hosny, K. M., Al-Sawahli, M. M., & Fahmy, U. A. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s76194 · Cited by 56
Optimizing Cardiovascular Outcomes in Diabetes Mellitus
Sobel, B. E. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.002 · Cited by 56
Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis
de Vries, F. M., Kolthof, J., Postma, M. J., Denig, P., & Hak, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111247 · Cited by 56
Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome
Fuentes, B., Martínez‐Sánchez, P., & Díez‐Tejedor, E. (2009) · Cerebrovascular Diseases · doi:10.1159/000200450 · Cited by 53
Dyslipidaemia in the Middle East: Current status and a call for action
Al‐Rasadi, K., Almahmeed, W. A., AlHabib, K. F., Abifadel, M., Farhan, H. A., Alsifri, S. N., Jambart, S., Zubaid, M., Awan, Z. A., Al-Waili, K., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.925 · Cited by 53
Patterns and predictors of statin prescription in patients with type 2 diabetes
Berthold, H. K., Gouni‐Berthold, I., Böhm, M., Krone, W., & Bestehorn, K. P. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-25 · Cited by 49
The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis
Goldfarb‐Rumyantzev, A. S., Habib, A. N., Baird, B. C., Barenbaum, L. L., & Cheung, A. K. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.023 · Cited by 47
Treatment Goals in Diabetes
Melmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 53
Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: A meta-analysis of prospective cohort studies
Wang, Y., Lammi‐Keefe, C. J., Hou, L., & Hu, G. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.07.009 · Cited by 46
Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding
Weiner, M. G., Xie, D., & Tannen, R. L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1585 · Cited by 46
Lipid re-screening: what is the best measure and interval?
Takahashi, O., Glasziou, P., Perera, R., Shimbo, T., Suwa, J., Hiramatsu, S., & Fukui, T. (2009) · Heart · doi:10.1136/hrt.2009.172619 · Cited by 46
Grounded Theory-Based Research within Exercise Psychology: A Critical Review
Hutchison, A. J., Johnston, L., & Breckon, J. (2011) · Qualitative Research in Psychology · doi:10.1080/14780880903304527 · Cited by 45
Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial
Buhse, S., hlhauser, I. M. X. F., Heller, T., Kuniß, N., ller, U. A. M., Kasper, J., Lehmann, T. N., & Lenz, M. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009116 · Cited by 44
Statin adherence and the risk of major coronary events in patients with diabetes: a nested case–control study
Ruokoniemi, P. T., Korhonen, M. J., Helin‐Salmivaara, A., Lavikainen, P., Jula, A., Junnila, S. Y. T., Kettunen, R., & Huupponen, R. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03895.x · Cited by 43
Statin Prescribing in the Elderly in the Netherlands
Vooght, M. G.-D., der Zee, A. H. M., Schalekamp, T., Mantel-Teeuwisse, A. K., & Jansen, P. A. F. (2010) · Drugs & Aging · doi:10.2165/11537330-000000000-00000 · Cited by 41
Effect of atorvastatin on endothelial function and inflammation in long‐duration type 1 diabetic patients without coronary heart disease and arterial hypertension
Konduracka, E., Galicka-Latała, D., Cieślik, G., Rostoff, P., Fedak, D., Sieradzki, J., Naskalski, J. W., & Piwowarska, W. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00798.x · Cited by 41
The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes
Dorfmeister, B., Cooper, J. A., Stephens, J. W., Ireland, H., Hurel, S. J., Humphries, S. E., & Talmud, P. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.11.008 · Cited by 41
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy
Lamas, G. A., Boineau, R., Goertz, C., Mark, D. B., Rosenberg, Y., Stylianou, M. P., Rozema, T. C., Nahin, R. L., Chappell, L. T., Lindblad, L., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.02.012 · Cited by 40
Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: A large population-based study
Baviera, M., Monesi, L., Marzona, I., Avanzini, F., Monesi, G., Nobili, A., Tettamanti, M., Riva, E., Cortesi, L., Bortolotti, A., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.004 · Cited by 40
The role of fenofibrate in clinical practice
Zambon, A., & Cusi, K. J. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.053 · Cited by 40
Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials
Naci, H., Brugts, J. J., Fleurence, R., & Ades, A. E. (2013) · QJM · doi:10.1093/qjmed/hct041 · Cited by 38
Lipids in health and disease
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 41
Prevalence and Pattern of Dyslipidemia and Its Associated Factors Among Patients with Type 2 Diabetes Mellitus in Jordan: A Cross-Sectional Study
Quran, T. M. A., Bataineh, Z. A., Al-Mistarehi, A.-H. W., Alaabdin, A. M. Z., Allan, H., Qura’an, A. A., Weshah, S. M., Alanazi, A. A., & Khader, Y. S. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s377463 · Cited by 39
Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist
Cavender, M. A., & Lincoff, A. M. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11539500-000000000-00000 · Cited by 39
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin
Kashi, Z., Mahrooz, A., Kianmehr, A., & Alizadeh, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151543 · Cited by 40
Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 38
Effect of Pioglitazone Compared with Glimepiride on Carotid Intima-media Thickness in Type 2 Diabetes
Mazzone, T. (2007) · US Cardiology Review · doi:10.15420/usc.2007.4.1.25 · Cited by 38
Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida
Fuentes, B., Gállego, J., Gil-Núñez, A., Morales, A., Purroy, F. F., Roquer, J., Segura, T., Tejada, J., Lago, A. P., Díez‐Tejedor, E., et al. (2011) · Neurología · doi:10.1016/j.nrl.2011.06.002 · Cited by 39
Screening for hyperglycemia in the developing world: Rationale, challenges and opportunities
Echouffo-Tcheugui, J. B., Mayige, M. T., Ogbera, A. O., Sobngwi, E., & Kengne, A. P. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.003 · Cited by 35

Authors: Costa, J., Borges, M., David, C., & Carneiro, A. V.
Affiliations: University of Lisbon (PT)
Hospital de Santa Maria (PT)
ORCID: Costa, João
Carneiro, António Vaz
Venue: BMJ
Publisher: BMJ
Published: 2006-04-03
Volume: 332
Issue: 7550
Pages: 1115-1124
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.38793.468449.ae
PMC: PMC1459619
OpenAlex: W2141819264
Cited by: 340
References: 69
Citations by year: 2026: 1 · 2025: 14 · 2024: 7 · 2023: 6 · 2022: 13 · 2021: 9 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 6 · 2016: 12 · 2015: 13 · 2014: 20 · 2013: 24 · 2012: 18
FWCI: 7.90
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
HighWire Press Open Archive (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: lipid-lowering drugs, statins, diabetes mellitus, coronary artery disease, major coronary events, primary prevention, secondary prevention, cardiovascular risk reduction, myocardial infarction, coronary revascularization, lipid lowering
MeSH terms: Hypolipidemic Agents, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Lipids, Myocardial Infarction, Myocardial Revascularization, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks